{"id":"NCT00353496","sponsor":"Ipsen","briefTitle":"Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours","officialTitle":"Phase III, Randomised, Double-blind, Stratified Comparative, Placebo Controlled, Parallel Group, Multi-centre Study to Assess the Effect of Deep Subcutaneous Injections of Lanreotide Autogel 120mg Administered Every 28 Days on Tumour Progression Free Survival in Patients With Non-functioning Entero-pancreatic Endocrine Tumour","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-06","primaryCompletion":"2013-04","completion":"2013-04","firstPosted":"2006-07-18","resultsPosted":"2015-02-18","lastUpdate":"2025-03-05"},"enrollment":264,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Endocrine Tumors"],"interventions":[{"type":"DRUG","name":"lanreotide (Autogel formulation)","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"lanreotide (Autogel formulation)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The study will compare the difference between lanreotide Autogel and placebo on progression free survival in patients who have an endocrine tumour in the pancreas or intestines.","primaryOutcome":{"measure":"Progression-Free Survival (PFS)","timeFrame":"From randomisation up to the last tumour assessment (scheduled at 96 weeks). Radiological scans were performed every 12 weeks during the first year and every 24 weeks during the second year","effectByArm":[{"arm":"Lanreotide (Autogel Formulation)","deltaMin":null,"sd":null},{"arm":"Placebo","deltaMin":72,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":71,"countries":["United States","Austria","Belgium","Czechia","Denmark","France","Germany","India","Italy","Netherlands","Poland","Slovakia","Spain","Sweden","United Kingdom"]},"refs":{"pmids":["25014687","33052555","25408662"],"seeAlso":["https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2023/05/05101856/CLARINET-Clinical-Lay-summary.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":25,"n":101},"commonTop":["Diarrhoea","Abdominal pain","Nausea","Fatigue","Headache"]}}